Browsing Leishmaniasis/Kala Azar by Authors
Development and External Validation of a Clinical Prognostic Score for Death in Visceral Leishmaniasis Patients in a High HIV Co-Infection Burden Area in EthiopiaAbongomera, C; Ritmeijer, K; Vogt, F; Buyze, J; Mekonnen, Z; Admassu, H; Colebunders, R; Mohammed, R; Lynen, L; Diro, E; et al. (Public Library of Science, 2017-06-05)In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to optimal management and reduction of these case fatality rates. We aimed to identify predictors of death from VL, and to develop and externally validate a clinical prognostic score for death in VL patients, in a high HIV co-infection burden area in Ethiopia.
A Randomized Trial of AmBisome Monotherapy and AmBisome and Miltefosine Combination to Treat Visceral leishmaniasis in HIV Co-infected Patients in EthiopiaDiro, E; Blesson, S; Edwards, T; Ritmeijer, K; Fikre, H; Admassu, H; Kibret, A; Ellis, SJ; Bardonneau, C; Zijlstra, EE; et al. (Public Library of Science, 2019-01-17)Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a lower dose of AmBisome with miltefosine would show acceptable efficacy at the end of treatment.
The Risk and Predictors of Visceral Leishmaniasis Relapse in HIV Co-infected Patients in Ethiopia: A Retrospective Cohort StudyAbongomera, C; Diro, E; Vogt, F; Tsoumanis, A; Mekonnen, Z; Admassu, H; Colebunders, R; Mohammed, R; Ritmeijer, K; van Griensven, J (Oxford University Press, 2017-07-20)